Patent · US Active

Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors

US11311520B2 · kind B2 · utility

0Cited by

0References

7Claims

0Family size

Assignees

Bayer Pharma Aktiengesellschaft · DE
BAYER HEALTHCARE LLC · DE

Inventors

Ulrich Klar · Berlin, DE
Rolf Bohlmann · Berlin, DE
Heike Schäcke · Berlin, DE
Detlev Sülzle · Berlin, DE
Stephan MENZ · Berlin, DE
Olaf Panknin · Berlin, DE

Key dates

Filing date	Aug 3, 2020
Grant date	Apr 26, 2022
Priority date	—
Expiry date	Aug 3, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.